Table 2.

AS followup characteristics of patients with GG1 disease at time of enrollment into National Cancer Institute AS program

	Total (103 pts)		Unilat (72 pts)		Bilat (31 pts)		p Value
Median mos on AS (IQR)	34 (23.5–52.5)		36.5 (27.75–57.25)		25 (14–42)		0.0046*
Followup biopsies:
Total No.	203		145		56
Median (IQR)	2	(1–3)	2	(1–3)	2	(1–2)	0.35
1 (%)	48	(46.6)	34	(23.45)	15	(26.79)	0.99
2 (%)	25	(24.27)	14	(9.66)	11	(19.64)	0.14
3 (%)	20	(19.42)	16	(11.03)	3	(5.36)	0.22
>4 (%)	10	(9.71)	8	(5.52)	2	(3.57)	0.71
Median mos time between each biopsy (IQR)	16	(12–27)	16	(12–29)	15	(12–25)	0.44
Median mos time between each MRI (IQR)	13	(12–16)	13	(12–16)	13	(12–15)	0.85
No. pts with AS grade progression on followup biopsy (%):
Total	49	(47.5)	30	(41.67)	19	(61.29)	0.11†
Upgrade on Sbx only	9	(18.4)	4	(13.3)	5	(26.3)	0.17
Upgrade on Tbx only	14	(28.6)	12	(40.0)	2	(10.5)	0.29
Upgrade on both	26	(53.1)	14	(46.7)	12	(63.2)	0.07

^*Mann-Whitney U test, p <0.05.

^†Chi-squared statistic.